Markets:

Overview

News

Currencies

International

Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

2.020 -0.020 (-0.98%)

Streaming Delayed Price Updated: 9:48 AM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4

March 28, 2023

OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4

Via News Direct

OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4

March 28, 2023

By David Willey, Benzinga

Via TheNewswire.com

OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4 ↗

March 28, 2023

Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...

Via Benzinga

OKYO Pharma Announces PDMR Dealing

March 24, 2023

From OKYO Pharma LTD

Via GlobeNewswire

OKYO Pharma's Trial Treating Subjects With DED Gets Listed On ClinicalTrials.gov ↗

March 17, 2023

OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public...

Via Benzinga

Why Is Okyo Pharma (OKYO) Stock Up 13% Today? ↗

March 16, 2023

Okyo Pharma (OKYO) stock is on the rise Thursday as investors react to news about its Phase 2 clinical trial of DED treatment OK-101.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 16, 2023

Via Benzinga

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

March 16, 2023

From OKYO Pharma LTD

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 14, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 14, 2023

Via Benzinga

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 14, 2023

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...

Via Benzinga

UBER, LYFT Stocks Rise as California Court Rules Drivers Are Contractors ↗

March 14, 2023

Uber (UBER) and Lyft (LYFT) stock are on the rise Tuesday after a court ruled that the companies' drivers are contractors.

Via InvestorPlace

Why Is OKYO Pharma (OKYO) Stock Down 10% Today? ↗

March 14, 2023

OKYO Pharma (OKYO) stock is heading lower on Tuesday after the company revealed details of a stock offering for its ADSs.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 14, 2023

Via Benzinga

Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket ↗

March 14, 2023

Gainers PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

March 14, 2023

We're starting off the day with an overview of the biggest pre-market stock movers investors need to keep an eye on for Tuesday!

Via InvestorPlace

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

March 14, 2023

From OKYO Pharma LTD

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 13, 2023

Via Benzinga

OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

March 13, 2023

From OKYO Pharma LTD

Via GlobeNewswire

SmallCapsDaily Interviews OKYO Pharma CEO Dr. Gary Jacob, PHD

March 10, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

March 01, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

US Stocks Edge Lower; Dollar Tree Profit Beats Views ↗

March 01, 2023

U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 30 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.09% to 32,626.82 while...

Via Benzinga

Why Is Helbiz (HLBZ) Stock Up 37% Today? ↗

March 01, 2023

Helbiz (HLBZ) stock is on the move Wednesday despite a lack of hard news concerning the electric bike and scooter company.

Via InvestorPlace

XPEV Stock Alert: What to Know as Xpeng Reports February Vehicle Deliveries ↗

March 01, 2023

Xpeng (XPEV) stock is worth checking on Wednesday after the electric vehicle (EV) company released delivery data for February.

Via InvestorPlace

Why Is Novavax (NVAX) Stock Down 26% Today? ↗

March 01, 2023

Novavax (NVAX) stock is dropping on Wednesday after the vaccine company warned investors about the state of its business.

Via InvestorPlace

Why Is OKYO Pharma (OKYO) Stock Down 31% Today? ↗

March 01, 2023

OKYO Pharma (OKYO) stock is taking a beating on Wednesday despite recent progress toward a Phase 2 clinical trial for dry eye treatment.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 01, 2023

Via Benzinga

OKYO Pharma's Drug OK-101 Clears Customs in the US; To Be Used In Phase 2, First-In-Human, Clinical Trial For Patients With Dry Eye Disease ↗

March 01, 2023

OKYO Pharma Limited (LSE: OKYO) (NASDAQ: OKYO) recently announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which was...

Via Benzinga

Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket ↗

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.